Neerincx, A H, Whiteson, K, Phan, J L, Brinkman, P, Abdel-Aziz, M I, Weersink, E J M, Altenburg, J, Majoor, C J, Maitland-van der Zee, A H, Bos, L D J, Haarman, E, Rutjes, N W, Terheggen-Lagro, S W J, Seljogi, D, Kemper, E M, Lutter, R, Vijverberg, S J, Vonk, S E M, Adriaens, N, Lub, R, van Brederode, M, van der Schaaf, L, Verkleij, M, van Gilst, N A, Hofsteenge, G H, Brackel, C L H, Lakeman, P, Bon, I C M, Tanner, S P M, Sterk, P J, Longo, C, Sinha, A, Fenn, D, Lammers, A, Richards, L B, van Bragt, J M, Kos, R, Dagelet, J W F, Lone-Latif, S J A, Schultz, M J, Smit, M R, Hagens, L A, Amsterdam mucociliary clearance disease research group & Amsterdam UMC Breath Research Group 2021, ' Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients ', ERJ Open Research, vol. 7, no. 2, 00731-2020 . https://doi.org/10.1183/23120541.00731-2020 ERJ Open Research, 7(2):00731-2020. BMJ Publishing Group ERJ Open Research article-version (VoR) Version of Record ERJ open research, 7(2):00731-2020. European Respiratory Society ERJ Open Research, Vol 7, Iss 2 (2021)